

**Brilliant Violet 421™ anti-human CD337 (NKp30)**

**Catalog # / Size:** 2226140 / 100 tests  
2226135 / 25 tests

**Clone:** P30-15

**Isotype:** Mouse IgG1, κ

**Immunogen:** Recombinant human NKp30


**Reactivity:** Human, Non-human primate, Other

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** V CD40.5

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD56 FITC and CD337 (clone P30-15) Brilliant Violet 421™ (left) or Mouse IgG1, κ Brilliant Violet 421™ isotype control (right) and CD56 FITC

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported applications (for the relevant formats) include: ELISA, stimulation of human NK cells via NKp30 in a redirected lysis assay, and blocking of NKp30 function in solution<sup>1,3,5</sup>.

**Application References:**

1. Stark S, *et al.* 2005. *J. Immunol. Methods* 296:149. (Block)
2. Mansater I, *et al.* 2008. *J. Immunol.* 181:1869. [PubMed](#)
3. Markel G, *et al.* 2009. *PLOS One* 4:e5597. (Block)
4. Correia DV, *et al.* 2011. *Blood* 118:992. (FC) [PubMed](#)
5. Byrd A, *et al.* 2007. *PLoS One.* 2:e1339. (Block)

**Description:** The p30-15 monoclonal antibody recognizes CD337 also known as activating NK receptor NKp30 (NKp30), and natural cytotoxicity triggering receptor 3. NKp30 is a type I transmembrane protein, member of the natural cytotoxicity receptor family that contains one immunoglobulin-like domain. NKp30 has an apparent molecular weight of 30 kD and six isoforms are produced by alternative splicing. NKp30 is expressed on resting and activated NK cells. NKp30 enhances NK cell cytotoxicity of tumor cells that are deficient in MHC class I molecules. NKp30 has been shown to associate with CD59 and TCR $\zeta$ . The p30-15 antibody against human NKp30 has been shown to be useful for flow cytometry, stimulation of human NK cells via NKp30 in a redirected lysis assay, and blocking of NKp30 function in solution.

**Antigen  
References:**

1. Pende D, *et al.* 1999. *J. Exp. Med.* 190:1505.